These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 28963352)

  • 1. mTOR and HDAC Inhibitors Converge on the TXNIP/Thioredoxin Pathway to Cause Catastrophic Oxidative Stress and Regression of RAS-Driven Tumors.
    Malone CF; Emerson C; Ingraham R; Barbosa W; Guerra S; Yoon H; Liu LL; Michor F; Haigis M; Macleod KF; Maertens O; Cichowski K
    Cancer Discov; 2017 Dec; 7(12):1450-1463. PubMed ID: 28963352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cotargeting MNK and MEK kinases induces the regression of NF1-mutant cancers.
    Lock R; Ingraham R; Maertens O; Miller AL; Weledji N; Legius E; Konicek BM; Yan SC; Graff JR; Cichowski K
    J Clin Invest; 2016 Jun; 126(6):2181-90. PubMed ID: 27159396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Compensatory combination of mTOR and TrxR inhibitors to cause oxidative stress and regression of tumors.
    Xia Y; Chen J; Yu Y; Wu F; Shen X; Qiu C; Zhang T; Hong L; Zheng P; Shao R; Xu C; Wu F; Chen W; Xie C; Cui R; Zou P
    Theranostics; 2021; 11(9):4335-4350. PubMed ID: 33754064
    [No Abstract]   [Full Text] [Related]  

  • 4. Metabolic synthetic lethality by targeting NOP56 and mTOR in KRAS-mutant lung cancer.
    Yang Z; Liang SQ; Zhao L; Yang H; Marti TM; Hegedüs B; Gao Y; Zheng B; Chen C; Wang W; Dorn P; Kocher GJ; Schmid RA; Peng RW
    J Exp Clin Cancer Res; 2022 Jan; 41(1):25. PubMed ID: 35039048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. mTOR kinase inhibitors synergize with histone deacetylase inhibitors to kill B-cell acute lymphoblastic leukemia cells.
    Beagle BR; Nguyen DM; Mallya S; Tang SS; Lu M; Zeng Z; Konopleva M; Vo TT; Fruman DA
    Oncotarget; 2015 Feb; 6(4):2088-100. PubMed ID: 25576920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncogenic activation of the PI3K/Akt pathway promotes cellular glucose uptake by downregulating the expression of thioredoxin-interacting protein.
    Hong SY; Yu FX; Luo Y; Hagen T
    Cell Signal; 2016 May; 28(5):377-383. PubMed ID: 26826652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth inhibition of pancreatic cancer cells by histone deacetylase inhibitor belinostat through suppression of multiple pathways including HIF, NFkB, and mTOR signaling in vitro and in vivo.
    Chien W; Lee DH; Zheng Y; Wuensche P; Alvarez R; Wen DL; Aribi AM; Thean SM; Doan NB; Said JW; Koeffler HP
    Mol Carcinog; 2014 Sep; 53(9):722-35. PubMed ID: 23475695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thioredoxin-interacting protein deficiency ameliorates diabetic retinal angiogenesis.
    Duan J; Du C; Shi Y; Liu D; Ma J
    Int J Biochem Cell Biol; 2018 Jan; 94():61-70. PubMed ID: 29203232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib.
    Acquaviva J; Smith DL; Sang J; Friedland JC; He S; Sequeira M; Zhang C; Wada Y; Proia DA
    Mol Cancer Ther; 2012 Dec; 11(12):2633-43. PubMed ID: 23012248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells.
    Lernoux M; Schnekenburger M; Losson H; Vermeulen K; Hahn H; Gérard D; Lee JY; Mazumder A; Ahamed M; Christov C; Kim DW; Dicato M; Bormans G; Han BW; Diederich M
    Clin Epigenetics; 2020 May; 12(1):69. PubMed ID: 32430012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defining key signaling nodes and therapeutic biomarkers in NF1-mutant cancers.
    Malone CF; Fromm JA; Maertens O; DeRaedt T; Ingraham R; Cichowski K
    Cancer Discov; 2014 Sep; 4(9):1062-73. PubMed ID: 24913553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. mTORC1/C2 and pan-HDAC inhibitors synergistically impair breast cancer growth by convergent AKT and polysome inhibiting mechanisms.
    Wilson-Edell KA; Yevtushenko MA; Rothschild DE; Rogers AN; Benz CC
    Breast Cancer Res Treat; 2014 Apr; 144(2):287-298. PubMed ID: 24562770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergy of WEE1 and mTOR Inhibition in Mutant
    Hai J; Liu S; Bufe L; Do K; Chen T; Wang X; Ng C; Li S; Tsao MS; Shapiro GI; Wong KK
    Clin Cancer Res; 2017 Nov; 23(22):6993-7005. PubMed ID: 28821559
    [No Abstract]   [Full Text] [Related]  

  • 14. Loss of RasGAP Tumor Suppressors Underlies the Aggressive Nature of Luminal B Breast Cancers.
    Olsen SN; Wronski A; Castaño Z; Dake B; Malone C; De Raedt T; Enos M; DeRose YS; Zhou W; Guerra S; Loda M; Welm A; Partridge AH; McAllister SS; Kuperwasser C; Cichowski K
    Cancer Discov; 2017 Feb; 7(2):202-217. PubMed ID: 27974415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TXNIP potentiates Redd1-induced mTOR suppression through stabilization of Redd1.
    Jin HO; Seo SK; Kim YS; Woo SH; Lee KH; Yi JY; Lee SJ; Choe TB; Lee JH; An S; Hong SI; Park IC
    Oncogene; 2011 Sep; 30(35):3792-801. PubMed ID: 21460850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Curbing autophagy and histone deacetylases to kill cancer cells.
    Gammoh N; Marks PA; Jiang X
    Autophagy; 2012 Oct; 8(10):1521-2. PubMed ID: 22894919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors.
    Dembla V; Groisberg R; Hess K; Fu S; Wheler J; Hong DS; Janku F; Zinner R; Piha-Paul SA; Ravi V; Benjamin RS; Patel S; Somaiah N; Herzog CE; Karp DD; Roszik J; Meric-Bernstam F; Subbiah V
    Sci Rep; 2017 Nov; 7(1):15963. PubMed ID: 29162825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TXNIP deficiency mitigates podocyte apoptosis via restraining the activation of mTOR or p38 MAPK signaling in diabetic nephropathy.
    Song S; Qiu D; Wang Y; Wei J; Wu H; Wu M; Wang S; Zhou X; Shi Y; Duan H
    Exp Cell Res; 2020 Mar; 388(2):111862. PubMed ID: 31982382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Roles of thioredoxin binding protein (TXNIP) in oxidative stress, apoptosis and cancer.
    Zhou J; Chng WJ
    Mitochondrion; 2013 May; 13(3):163-9. PubMed ID: 22750447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic and oncogenic inhibitors cooperatively drive differentiation and kill KRAS-mutant colorectal cancers.
    Loi P; Schade AE; Rodriguez CL; Krishnan A; Perurena N; Nguyen VTM; Xu Y; Watanabe M; Davis RA; Gardner A; Pilla NF; Mattioli K; Popow O; Gunduz N; Lannagan TRM; Fitzgerald S; Sicinska ET; Lin JR; Tan W; Brais LK; Haigis KM; Giannakis M; Ng K; Santagata S; Helin K; Sansom OJ; Cichowski K
    Cancer Discov; 2024 Aug; ():. PubMed ID: 39121480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.